Akèy › Miasteni grav
Etid klinik pou Miasteni grav ap rekrite nan Etazini
45 etid pou Miasteni grav ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Tampa, FL12 etid
- Houston, TX11 etid
- Boca Raton, FL10 etid
- Durham, NC10 etid
- Columbus, OH8 etid
- St. Louis, MO7 etid
- Miami, FL7 etid
- Milwaukee, WI7 etid
- New York City, NY7 etid
- Chattanooga, TN6 etid
- Charleston, SC6 etid
- Jacksonville, FL6 etid
- San Francisco, CA6 etid
- Detroit, MI6 etid
- Washington, DC6 etid
- Dallas, TX6 etid
- Orange, CA6 etid
- Columbia, MO6 etid
- Kansas City, KS6 etid
- Austin, TX6 etid
- Philadelphia, PA6 etid
- Portland, OR6 etid
- Boston, MA6 etid
- Cincinnati, OH5 etid
- Lexington, KY5 etid
- Port Charlotte, FL5 etid
- Scottsdale, AZ5 etid
- Aurora, CO5 etid
- New Haven, CT4 etid
- Los Angeles, CA4 etid
- Augusta, GA4 etid
- Amherst, NY4 etid
- Chicago, IL4 etid
- Mountain View, CA4 etid
- Las Vegas, NV3 etid
- Clearwater, FL3 etid
- Lansing, MI3 etid
- Raleigh, NC3 etid
- Phoenix, AZ3 etid
- Carlsbad, CA3 etid
Pa eta
- Arizona7 etid
- Colorado8 etid
- Connecticut6 etid
- Distrik Columbia6 etid
- Florid22 etid
- Georgia4 etid
- Illinois12 etid
- Indiana3 etid
- Kalifòni20 etid
- Kansas7 etid
- Kentucky6 etid
- Massachusetts11 etid
- Michigan12 etid
- Minnesota3 etid
- Missouri7 etid
- Nevada3 etid
- New Jersey3 etid
- New York13 etid
- North Carolina14 etid
- Ohio13 etid
- Oregon8 etid
- Pennsylvania6 etid
- South Carolina7 etid
- Tennessee10 etid
- Texas18 etid
- Virginia3 etid
- Wisconsin7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07787247A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07647510Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT07217587A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07463521ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07284420ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07294170ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07673627A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07465289A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07673744Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06463587A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07501702A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06680037A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Ap rekriteFaz 2
Laj 2 a 17 · Tout sèks · Mizajou Sep 1, 2026 · NCT06987539Zilucoplan for Severe gMG Exacerbations
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07215949Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06414954AXIS MG Patient Registry
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07761026A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 14, 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Aug 13, 2026 · NCT06359041Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 64 · Fanm · Mizajou Aug 11, 2026 · NCT06940323MuSK Myasthenia 1000 Study
Ap rekriteEtid obsèvasyon
Laj 7 a 99 · Tout sèks · Mizajou Aug 5, 2026 · NCT06259071Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Ap rekriteFaz 1/2
Laj 18 a 85 · Tout sèks · Mizajou Aug 3, 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Ap rekriteFaz 2/3
Laj 2 a 17 · Tout sèks · Mizajou Jul 31, 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Jul 29, 2026 · NCT06193889A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT04951622Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.